- Report
- January 2021
- 78 Pages
Middle East, Africa
From €1450EUR$1,500USD£1,246GBP
- Report
- November 2022
- 160 Pages
Global
€3287EUR$3,400USD£2,823GBP
- Drug Pipelines
- October 2020
- 95 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- September 2019
- 18 Pages
Global
€9668EUR$10,000USD£8,304GBP
- Report
- November 2023
- 107 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Report
- March 2024
- 132 Pages
Global
From €918EUR$950USD£789GBP
- Report
- February 2024
- 146 Pages
Global
From €3480EUR$3,600USD£2,990GBP
- Report
- February 2024
- 217 Pages
Global
From €3480EUR$3,600USD£2,990GBP
- Report
- November 2022
- 310 Pages
Global
From €5888EUR$6,090USD£5,057GBP
- Report
- November 2020
- 294 Pages
Global
From €4741EUR$4,904USD£4,072GBP
- Report
- April 2020
- 197 Pages
Global
From €5192EUR$5,370USD£4,459GBP
- Report
- May 2023
- 147 Pages
Global
From €5800EUR$5,999USD£4,982GBP
- Book
- June 2015
- 392 Pages
- Book
- October 2012
- 1570 Pages
The Meningococcal Vaccine is a type of vaccine used to protect against meningococcal disease, a serious and potentially fatal infection caused by the bacterium Neisseria meningitidis. It is recommended for adolescents and young adults, as well as for those at increased risk of infection, such as travelers to certain countries and those with certain medical conditions. The vaccine is available in both conjugate and polysaccharide forms, and is typically administered in two or three doses.
The Meningococcal Vaccine market is part of the larger Infectious Diseases Drugs market, which includes a range of treatments for various infectious diseases. The Meningococcal Vaccine market is expected to grow in the coming years, driven by increasing awareness of the disease and the availability of new vaccines.
Some companies in the Meningococcal Vaccine market include GlaxoSmithKline, Merck, Pfizer, Sanofi, and Novartis. Show Less Read more
